Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Dora Stölzl; Nicole Sander; Annice Heratizadeh; Eva Haufe; Inken Harder; Susanne Abraham; Luise Heinrich; Andreas Kleinheinz; Andreas Wollenberg; Elke Weißhaar; Knut Schäkel; Konstantin Ertner; Franca Wiemers; Julia Wildberger; Margitta Worm; Ralph von Kiedrowski; Isaak Effendy; Andrea Asmussen; Matthias Augustin; M. Pawlak; Michael Sticherling; Alexander Zink; M. Hilgers; Christiane Handrick; Sven Quist; Beate Schwarz; Petra Staubach; M. Bell; Sun-Hei Hong-Weldemann; Bernhard Homey; Jens‐Joachim Brücher; Jochen Schmitt; Thomas Werfel; Stephan Weidinger

doi:10.1111/bjd.21794

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stölzl et al. (2022) studied this question.

synapsesocial.com/papers/6aae09b01106761094a35c64 https://doi.org/10.1111/bjd.21794

View Full Paper

Ask AI

Bookmark

Share

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Ask about this paper

Abstract

Discussion

Cite This Study

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading